Please assess the completion status of the following clinical trial:

Trial Title: A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Postherpetic Neuralgia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Visual Analogue Scale (VAS) of pain is higher than 40 mm.~* Pain is sustained for more than 3 months after healing of herpes zoster skin rash.~Exclusion Criteria:~* Malignancy within the past 2 years.~* Patients who have undergone neurolytic or neurosurgical therapy for postherpetic neuralgia.~* Creatinine clearance \</= 30 mL/min (estimated from serum creatinine, body weight, age, and sex using the Cockcroft and Gault equation, by omitting any decimal fractions).~* Patients having other severe pain which may impair the self assessment of the pain due to postherpetic neuralgia.~* Skin conditions in the affected dermatome that could alter sensation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Pregabalin 150mg/day (Type: EXPERIMENTAL): None
- Pregabalin 300mg/day (Type: EXPERIMENTAL): None
- Pregabalin 600mg/day (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).